实时全球研报
There’s nothing uniform about CTAS’ premium growth; U/G to Buy, PO to $230
研报英文原文证据摘录
There’s nothing uniform about CTAS’ premium growth; U/G to Buy, PO to $230
Upgrade CTAS to Buy; PO to $230
We are upgrading Cintas to Buy and raising our PO to $230 following better than
expected fiscal 4Q26 results (see recap on pg. 5) as well as FY27 guidance that likely
leans conservative. We are incrementally more constructive on the setup for earnings
over the next several quarters as Cintas benefits from an improved backdrop in key labor
verticals, continues to drive impressive growth in adjacent product categories and is
generating outsized margin gains from a high focus on improving supply chain and
distribution efficiencies. With shares trading at a discount to the 5yr average (11%
lower), we see an opportunity for re-rating on better-than-expected results and as
investors give more credit for Cintas’ best in class execution, “all-weather” growth
model and durable HSD organic revenue expansion that continues to lead business
services peers.
We increase our PO to $230 (from $200) as we move our basis to align with 2027
calendar year end (fiscal 2Q27 ending in Nov. ‘28 for Cintas) from ‘27 fiscal year (ending
in May’ 27) previously and now based on 39x P/E (from 37x prior).
Upside opportunities start with the right adjacencies
Going into FY27, we remain constructive on several potential upside drivers. First, we
see continued strength in the high-margin First Aid segment after CTAS reported
organic growth of 13.2% in 4Q26 despite a difficult comparison (+18.5% in 4Q25, aided
by a one-time gain). Additionally, the segment’s gross margins grew 110bps y/y to
57.9% (from 56.8% in 4Q25). Growth remains supported by strong new business wins,
cross-selling within the existing customer base, and continued customer penetration
across a large and underpenetrated market.
本摘录由系统从所标注的 PDF 证据页直接提取并保留英文原文,不做批量翻译;登录后在阅读器切换中文时才按需翻译。
打开研报阅读器